Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

CDK 4/6 inhibitors for metastatic breast cancer

Dr Giuseppe Curigliano, Dr Carmen Criscitiello, Dr Ghadeer Shubassi, Prof Pierfranco Conte
CDK 4/6 inhibitors for metastatic breast cancer ( Dr Giuseppe Curigliano, Dr Carmen Criscitiello, Dr Ghadeer Shubassi, Prof Pierfranco Conte )
20 Mar 2017

IMW 2017 highlights

Dr Laurent Garderet - Hôpital Saint Antoine, Paris, France
IMW 2017 highlights ( Dr Laurent Garderet - Hôpital Saint Antoine, Paris, France )
7 Mar 2017

Outcome of third salvage autologous stem cell transplantation in multiple myeloma

Dr Laurent Garderet - Hôpital Saint Antoine, Paris, France
Outcome of third salvage autologous stem cell transplantation in multiple myeloma ( Dr Laurent Garderet - Hôpital Saint Antoine, Paris, France )
7 Mar 2017

Evaluating efficacy of denosumab compared with zoledronic acid in symptomatic myeloma

Dr Noopar Raje - Massachusetts General Hospital, Boston, USA
Evaluating efficacy of denosumab compared with zoledronic acid in symptomatic myeloma ( Dr Noopar Raje - Massachusetts General Hospital, Boston, USA )
4 Mar 2017

Long term effects of myeloma treatment

Monica Morris - Myeloma UK, Edinburgh, UK
Long term effects of myeloma treatment ( Monica Morris - Myeloma UK, Edinburgh, UK )
3 Mar 2017

Update on CASTOR trial: Daratumumab, bortezomib, and dexamethasone for relapsed or refractory myeloma

Dr Suzanne Lentzsch - Columbia University, New York, USA
Update on CASTOR trial: Daratumumab, bortezomib, and dexamethasone for relapsed or refractory myeloma ( Dr Suzanne Lentzsch - Columbia University, New York, USA )
3 Mar 2017

Caring for multiple myeloma carers

Monica Morris - Myeloma UK, Edinburgh, UK
Caring for multiple myeloma carers ( Monica Morris - Myeloma UK, Edinburgh, UK )
3 Mar 2017

Impact of recurrent myeloma alterations on drug response

Dr Muntasir Mamun Majumder - University of Helsinki, Helsinki, Finland
Impact of recurrent myeloma alterations on drug response ( Dr Muntasir Mamun Majumder - University of Helsinki, Helsinki, Finland )
3 Mar 2017

What is the biology behind immunotherapy for MM?

Dr Alexander Lesokhin - Memorial Sloan Kettering Cancer Center, New York, USA
What is the biology behind immunotherapy for MM? ( Dr Alexander Lesokhin - Memorial Sloan Kettering Cancer Center, New York, USA )
3 Mar 2017

Carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma

Dr Ralph Boccia - Center for Cancer and Blood Disorders, Bethesda, USA
Carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma ( Dr Ralph Boccia - Center for Cancer and Blood Disorders, Bethesda, USA )
3 Mar 2017

Is precision myeloma medicine more hype than reality?

Dr Suzanne Lentzsch - Columbia University, New York, USA
Is precision myeloma medicine more hype than reality? ( Dr Suzanne Lentzsch - Columbia University, New York, USA )
3 Mar 2017

Asia-Pacific approaches to myeloma trials

Prof Chng Wee Joo - National University Health System, Singapore, Singapore
Asia-Pacific approaches to myeloma trials ( Prof Chng Wee Joo - National University Health System, Singapore, Singapore )
3 Mar 2017